Loading
NASDAQHealthcareBiotechnology
Latest quote
$29.73
+$0.22 · +0.75%
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
Previous close
$29.73
+$0.22 · +0.75%
Regular session · ET · Market data may be delayed.
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
Day range
Current $29.73
52-week range
Current $29.73
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
86
Deep Value
Sentiment
57
Mixed
Risk
27
Moderate Risk
Momentum
45
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
Day range
Current $29.73
52-week range
Current $29.73
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.11B EUR | 275.65M EUR | 239.72M EUR | 241.25M EUR | 234.38M EUR |
| Cost of goods sold | 29.74M EUR | 34.86M EUR | — | — | 320.5M EUR |
| Gross profit | 1.08B EUR | 240.79M EUR | 239.72M EUR | 241.25M EUR | −86.12M EUR |
| Research and development | 459.42M EUR | 335.46M EUR | 241.29M EUR | 269.8M EUR | 320.5M EUR |
| Selling, general, and administrative | 111.96M EUR | 96.88M EUR | 94.25M EUR | 103.31M EUR | 131.52M EUR |
| Operating expenses | 581.12M EUR | 429.12M EUR | 327.99M EUR | 372.31M EUR | 85.45M EUR |
| Interest income | 46.34M EUR | 89.77M EUR | 79.61M EUR | 18.09M EUR | — |
| Interest expense | 2.22M EUR | 911K EUR | 1.77M EUR | 9.16M EUR | 8.73M EUR |
| Depreciation and amortization | 55.88M EUR | 45.5M EUR | 43.64M EUR | 65.57M EUR | 8.31M EUR |
| Operating income | 501.39M EUR | −188.34M EUR | −88.26M EUR | −131.06M EUR | −171.57M EUR |
| Net income | 320.88M EUR | 74.08M EUR | 211.7M EUR | −217.99M EUR | −103.23M EUR |
Company facts updated Oct 10, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
